Inex Innovate Gets CE-IVD Mark for Its OvaCis Rapid Cancer Test

Singapore-based Inex Innovate has received a CE-IVD mark for its OvaCis rapid test for detection of cancer in ovarian cysts.

The point-of-care test is used to rapidly differentiate between benign and malignant ovarian cysts in operating theaters.

The company released a previous version of the product in 2018. The latest version extends the product's shelf-life to a minimum of 18 months when stored at room temperature.

The company intends to launch the upgraded test in the EU and Southeast Asia in the fourth quarter of this year.